SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients

Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk

For patients with diabetes subsequently diagnosed and hospitalized with COVID-19, use of a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) before COVID-19 infection is associated with lower COVID-19-related adverse outcomes, according to a systematic review and network meta-analysis published online Dec. 6 in JAMA Network Open.

T-DXd yields superior outcomes over chemotherapy-based regimens in patients previously treated with T-DM1

Previous article

Q and A: Teen stretch marks

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations